Skip to main content

Site notifications

AusPAR: Nuvaxovid

Australian Public Assessment Report
Device/Product Name
Nuvaxovid
Active ingredients
SARS-CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)
AusPAR Date
Published
Submission Number
PM-2022-01431-1-2
Submission Type
Extension of indications
Decision
Approved for provisional registration

Help us improve the Therapeutic Goods Administration site